LIST OF ABBREVIATIONS {#sec0005}
=====================

2-DG, 2-deoxy-D-glucose; *Acadl*, acyl-CoA dehydrogenase, long chain (also called *LCAD*); *Acads*, acyl-CoA dehydrogenase, short chain (also called *SCAD*); *Acadvl*, acyl-CoA dehydrogenase, very long chain (also called *VLCAD*); ActRIIB-Fc, soluble Activin receptor type IIB; *Alas1*, delta-aminolevulinic acid synthase 1; AMPK*α*, AMP-activated protein kinase alpha; ANOVA, analysis of variance; *Atp5o*, ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit; β2 *m*, β-2-microglobulin; BCA, bicinchoninic acid; Cas9, CRISPR-associated protein 9; *Cd36*, cluster of differentiation 36; CK, creatine kinase; *Cox*, cytochrome c oxidase; *Cpt*, carnitine palmitoyltransferase; CRISPR, clustered regularly interspaced short palindromic repeats; *Cs*, citrate synthase; *Cycs*, cytochrome c, somatic; DAPI, 4^′^,6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle's Medium; ECAR, extracellular acidification rate; ECL, electrochemiluminescence; EDL, extensor digitorum longus; EdU, 5-ethynyl-- 2^′^-deoxyuridine; *Eno3*, enolase 3 (beta, muscle); *Esrr*, estrogen related receptor; FACS, fluorescence-activated cell sorting; *Fasn*, fatty acid synthase; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GCN5L2, general control of amino acid synthesis, yeast, homolog-like 2; GDF-8, growth/differentiation factor 8 (myostatin); GDF-11, growth/differentiation factor 11; gRNA, guide RNA; GTEx, Genotype-Tissue Expression; *Hk2*, hexokinase 2; IGF-1, insulin-like growth factor-1; *Lipe*, hormone sensitive lipase (also called *HSL*); *Mss51*, *Mss51* mitochondrial translational activator; Mstn, myostatin; MyHC, myosin heavy chain; *Nfe2l2*, nuclear factor, erythroid 2-like 2 (also called *Nrf2*); *Nrf1*, nuclear respiratory factor-1; OCR, oxygen consumption rate; ORF, open reading frame; *Pdk4*, pyruvate dehydrogenase lipoamide kinase 4; *Pfk-1*, phosphofructokinase 1; *PGC1*, peroxisome-proliferator activated receptor gamma coactivator 1; *Pgk1*, phosphoglycerate kinase 1; *PPAR*, peroxisome-proliferator activated receptor; PVDF, polyvinylidene fluoride; qRT-PCR, quantitative reverse transcription polymerase chain reaction; RPKM, reads per kilobase per million reads mapped; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; *Sirt1*, sirtuin 1; *Slc2a4*, solute carrier family 2 member 4 (also called *Glut4*); *Socs7*, suppressor of cytokine signaling 7; *Srebf1*, sterol regulatory element binding transcription factor 1; SUnSET, Surface Sensing of Translation; *TBP*, TATA box binding protein; TBS, Tris-buffered saline; *Tfam*, transcription factor A, mitochondrial; TGF-β, transforming growth factor β; *Ucp*, uncoupling protein; VDAC, voltage-dependent anion channel; WVL, white vastus lateralis; Zmynd17, zinc-finger MYND-domain containing protein 17.

INTRODUCTION {#sec0010}
============

Myostatin, or growth/differentiation factor 8 (GDF-8), is a member of the TGF-β superfamily and a negative regulator of muscle growth \[[@r1]\]. Myostatin inhibition has been shown to increase regeneration and decrease fibrosis of skeletal muscle and is thus of high interest for the treatment of acquired and inherited conditions where muscle is not able to regenerate efficiently \[[@r2]\]. An important additional feature of myostatin inhibition that may indicate potential therapeutic use in insulin resistance and obesity is its modulation of skeletal muscle metabolism \[[@r8]\]. Constitutive deletion of myostatin leads to changes in fiber type composition of skeletal muscle with a decrease in type I/type IIA oxidative fibers and an increase in type IIB glycolytic fibers \[[@r9]\]. Myostatin deletion or postnatal inhibition improves insulin sensitivity, increases glucose uptake into skeletal muscle and decreases total body fat \[[@r12]\]. Myostatin deletion suppresses fat accumulation and abnormal glucose metabolism in agouti lethal yellow (A(y)) and obese (ob/ob) mice and transgenic overexpression of a dominant negative activin receptor type IIB resolves the severe diabetes of the lipodystrophy A-ZIP mouse \[[@r15]\]. Treating mice fed high-fat diets with postnatal inhibitors of myostatin reduces the development of insulin resistance and fat accumulation \[[@r17]\]. However, the specific targets of myostatin and other TGF-β family members on genes producing these metabolic effects have not been clarified.

In a previous study, we profiled gene expression in skeletal muscle of mice treated with a soluble activin type IIB receptor (ActRIIB-Fc), the putative receptor of myostatin and activin A \[[@r19]\]. One of the genes whose expression was most significantly altered was *Mss51* mitochondrial translational activator, named after its putative yeast homolog *Mss51* and previously known as *Zmynd17*. *Mss51* was downregulated 4.3-fold in response to acute, and 3.3-fold in response to chronic treatment with ActRIIB-Fc, suggesting that *Mss51* might be an effector or downstream target of myostatin or activin A \[[@r19]\].

Similar results have been seen in numerous other published studies. *Mss51* was downregulated 2.7-fold in skeletal muscle of mice where the myostatin gene was deleted post-developmentally \[[@r20]\], 2.8-fold when mice were treated with myostatin neutralizing antibody JA16 \[[@r21]\] and 4.8-fold in transgenic mice expressing a skeletal-muscle specific, myostatin inhibitory pro-peptide \[[@r22]\]. Additionally, *Mss51* expression decreased 2.2-fold in skeletal muscle of transgenic mice expressing a skeletal muscle-specific dominant negative TGF-β receptor \[[@r23]\]. The consistent downregulation of *Mss51* expression in response to numerous methods of postnatal TGF-β superfamily inhibition suggested that *Mss51* might have a unifying role in skeletal muscle function.

The function of *Mss51* in mammals has not been previously reported. In the yeast *Saccharomyces cerevisiae*, *Mss51* couples the synthesis of cytochrome *c* oxidase subunit 1 (COX1) to the assembly of the cytochrome *c* oxidase complex of the respiratory chain in the mitochondria \[[@r24]\]. Yeast *Mss51* also senses heme and oxygen availability to regulate cytochrome *c* oxidase biogenesis \[[@r25]\]. Iterative orthology prediction using Ortho-Profile demonstrated that the human *MSS51* protein is a putative homolog of the yeast *Mss51* protein, and that human *MSS51* has a mitochondrial localization signal \[[@r26]\]. However, a global pairwise alignment (using the Needleman-Wunsch algorithm) between yeast *Mss51* \[NCBI RefSeq: NP_013304.1\] and mouse *Mss51* \[RefSeq: NP_083380.1\] revealed only 19% amino acid identity (91/490 residues). This suggested that *Mss51*, a newly recognized target of myostatin and other TGF-β family member signaling, may have a novel function in mammals. Here we investigate the expression and function of *Mss51* in skeletal muscle.

MATERIALS AND METHODS {#sec0015}
=====================

Cell culture {#sec0020}
------------

C2C12 cells (ATCC, Manassas, VA) were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO). Differentiation was induced when cells reached approximately 80% confluence by switching to differentiation medium, DMEM supplemented with 2% horse serum (Life Technologies). Cells were treated with growth factors or inhibitors after three days of differentiation. For treatment with the inhibitors ActRIIB-Fc (generously provided by Qian Wang, Stony Brook University Medical Center, produced as previously described \[[@r27]\]) and TGF-β1/2/3 neutralizing antibody 1D11 (R&D Systems, Minneapolis, MN), media was changed to DMEM supplemented with 0.1% bovine serum albumin 24 hours before the addition of the inhibitors. For treatment with recombinant myostatin, activin A, TGF-β1 and insulin-like growth factor 1 (IGF-1) (all obtained from R&D Systems), media was changed to DMEM supplemented with 0.1% bovine serum albumin and the indicated growth factor on the third day post differentiation media change. For all treatments, cells were incubated for 5 hours and harvested in TRIzol (Life Technologies) for qRT-PCR analysis.

Skeletal muscle acquisition {#sec0025}
---------------------------

Skeletal muscle was obtained from mice for qRT-PCR and humans for subcellular fractionation and Western blots. All animal experiments were conducted in accordance with the guidelines prescribed by the Institutional Animal Care and Use Committee at the Johns Hopkins University School of Medicine. Ten to twelve week-old female C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) were maintained under a 12:12 hour light:dark schedule with *ad libitum* access to food and water. Mice were euthanized by inhalation overdose of isoflurane followed by cervical dislocation. From three mice, the brain, heart, kidney, liver, small intestine, diaphragm, and quadriceps were harvested. From three other mice, the soleus, diaphragm, long head of the triceps, extensor digitorum longus (EDL), and white vastus lateralis (WVL) were harvested. Tissues were minced and frozen in TRIzol for qRT-PCR analysis.

Acquisition of human skeletal muscle was approved by the Johns Hopkins Medicine Institutional Review Board. Written informed consent was obtained for the collection and use of human tissue samples. Human samples of deltoid muscle were obtained by open muscle biopsy of a living volunteer and from an autopsy donor and were stored frozen prior to subcellular fractionation.

CRISPR/Cas9-mediated disruption of *Mss51* locus in C2C12 cells {#sec0030}
---------------------------------------------------------------

In order to decrease *Mss51* expression, the *Mss51* genomic locus was disrupted in C2C12 cells using the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system for genome engineering \[[@r27]\]. Guide RNA (gRNA) target sequences and plasmids were designed and synthesized through the University of Massachusetts Medical School's Mutagenesis Core, which provided a plasmid expressing both the CRISPR gRNA and the RNA-guided DNA endonuclease Cas9 under independent promoters, as well as a reporter plasmid containing a non-functional GFP ORF, disrupted by homology arms flanking DNA sequence containing the *Mss51*-specific CRISPR target sequence \[[@r28]\]. Proliferating C2C12 cells were transfected with the CRISPR/Cas9 plasmid and disrupted GFP reporter plasmid using an Amaxa Nucleofector II and Cell Line Nucleofector Kit V (Lonza, Walkersville, MD, USA) according to manufacturer's instructions. The target sequence within *Mss51*, depicted in [Fig. 4A](#jnd-2-4-jnd150119-g004){ref-type="fig"}, was cleaved by the CRISPR/Cas9 complex and re-sealed by non-homologous end joining. Simultaneously, the CRISPR/Cas9 complex also cleaved the disrupted GFP reporter plasmid, which was re-sealed by homology-directed repair using the homology arms flanking the cut site, allowing for functional expression of GFP only when the CRISPR/Cas9 complex was present. After 24 hours, transfected cells were isolated by fluorescence-activated cell sorting using a FACSAria Ilu (BD Biosciences, Franklin Lakes, NJ, USA), shown schematically in [Fig. 4B](#jnd-2-4-jnd150119-g004){ref-type="fig"}. In parallel, control cells were transfected with a plasmid expressing functional GFP and subjected to the same cell sorting process as the *Mss51*-disrupted cells. Pooled populations of *Mss51*-disrupted and control cells were collected and expanded for comparative analysis. Cells were allowed to differentiate into myotubes for six days before analysis unless otherwise stated.

Cell proliferation and differentiation {#sec0035}
--------------------------------------

To compare rates of cell proliferation, incorporation of the nucleoside analog 5-ethynyl-- 2^′^-deoxyuridine (EdU) was measured using the Click-iT EdU Alexa Fluor 594 Imaging Kit per manufacturer's instructions (Life Technologies). To compare myotube differentiation, cells were stained with anti-sarcomeric myosin (MF20-s, DSHB, Iowa City, IA, USA, 1:1) after fixing with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA), permeabilizing with 0.1% Triton X-100 (Fisher Scientific, Hampton, NH, USA), and blocking with 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA). For both proliferation and differentiation, images were acquired using an EVOS FL Cell Imaging System equipped with a 20×/0.45 NA objective (Life Technologies). Images were analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA). The myofusion index was calculated as the percentage of nuclei that were found in MF20-positive fibers. As an additional measure of differentiation, creatine kinase (CK) activity was compared between control and *Mss51*-disrupted cells using the EnzyChrom Creatine Kinase Assay Kit (BioAssay Systems, Hayward, CA, USA) following the manufacturer's instructions.

Subcellular fractionation and western blot {#sec0040}
------------------------------------------

In order to separate nuclear, cytosolic, and mitochondrial fractions from human tissue, subcellular fractionation was performed as previously described \[[@r29]\] with minor modification. Tissue homogenization was performed with a Poltyron PT 10-- 35 benchtop homogenizer (Kinematica, Luzern, Switzerland) and 20 passes through a 20 G needle. Human tissue was used because at the time of these experiments, there were no available antibodies that selectively recognized mouse *Mss51*. The resulting fractions were then heat-denatured and reduced.

For Western blotting, cells were harvested in RIPA lysis buffer. Heat-denatured and reduced protein samples were separated by SDS-PAGE and transferred to PVDF membranes by standard techniques. To ensure equal protein loading, sample concentrations were measured using the bicinchoninic acid (BCA) assay. Membranes were blocked with 5% nonfat milk in TBS with 0.1% Tween 20 (TBS-T), probed with primary antibodies, washed, incubated with appropriate horseradish peroxidase-conjugated secondary antibodies in TBS-T, and developed using X-ray film and Amersham ECL Prime Western Blotting Detection Reagent (RPN2232; GE Healthcare Life Sciences, Pittsburgh, PA, USA). Primary antibodies used were anti-puromycin (PMY-2A4-s; Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA, USA; 1:200), anti-GAPDH (G9545; Sigma-Aldrich; 1:10,000), anti-Histone H3 (H0164; Sigma-Aldrich; 1:10,000), anti-VDAC (4866; Cell Signaling Technology (CST), Danvers, MA, USA; 1:1,000), anti-AMPK*α* (5831; CST; 1:1,000), and anti-phospho-AMPK*α* (2535; CST; 1:1,000). At the time of publication, the only *Mss51* antibody available is a human-specific, "anti-Zmynd17" (AP54659PU-N; Acris Antibodies, San Diego, CA, USA; 1:500).

Quantitative RT-PCR {#sec0045}
-------------------

Cells and tissues were homogenized in TRIzol, total RNA was isolated using the Direct-zol RNA MiniPrep Kit (Zymo Research, Irvine, CA, USA) and cDNA was synthesized from 1 microgram of RNA per sample using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). cDNA was diluted and used as the template for real-time PCR using a CFX Connect Real-Time PCR Detection System (Bio-Rad) and SYBR Green PCR Master Mix (Life Technologies). Relative gene expression was determined using the *ΔΔ*Ct method normalized to the indicated reference genes through the analytical software qbase+ (Biogazelle, Ghent, Belgium). At least three reference genes were included in each qRT-PCR experiment, and qbase+ was used to run the geNorm algorithm to select the most stable and suitable reference gene(s) for each experiment. Primer sequences are available upon request.

SUnSET assay {#sec0050}
------------

To assay relative rates of protein synthesis, the surface sensing of translation (SUnSET) assay was used as previously described \[[@r30]\]. Cells were incubated with 1*μ*M puromycin for 30 minutes before lysis in RIPA buffer with protease inhibitors, allowing for Western blot analysis of puromycin incorporation as a marker of protein synthesis. In addition to the gel that was used for Western blot analysis, a duplicate gel was stained with SYPRO Ruby protein gel stain (Life Technologies) following manufacturer's instructions for use in densitometry analysis normalization using ImageJ.

Metabolic assays {#sec0055}
----------------

For determination of cellular ATP content, cells were differentiated for 6 days and lysed in Reporter Lysis Buffer (Promega, Madison, WI, USA). The ATP Determination Kit (Life Technologies) was used according to manufacturer's instructions and data were normalized to the protein content of each well as determined by BCA assay.

β-Oxidation of \[1-^14^C\]palmitic acid (C16:0, Moravek Biochemicals Inc., Brea, CA, USA) to water-soluble products was measured in intact myotubes grown in 6-well plates. Fatty acid in benzene solution was dried under a stream of nitrogen in a glass tube and solubilized with 10 mg/ml *α*-cyclodextrin (Sigma-Aldrich) in 10 mM Tris-Cl^- ^, pH 8.0, to a final concentration of 0.1 mM and a specific activity of ∼30,000 dpm/nmol. After 6 days of differentiation, the culture medium was replaced with serum-free DMEM containing 10*μ*M solubilized radiolabeled palmitate and 2 mM L-carnitine. After 2 hours at 37°C, the reaction was stopped by adding ice-cold HClO~4~ (final concentration 3% ) to the medium. Plates were kept on ice for 1 hour before extraction of water soluble products using Folch partition as previously described \[[@r31]\]. The aqueous phase was mixed with Budget-Solve (RPI, Mount Prospect, IL, USA) and radioactivity was determined using a Beckman LS 6500 liquid scintillation spectrometer. Protein was determined in 5-6 wells of parallel 6-well plates by the method of Lowry et al. \[[@r32]\]. Results are presented as nmol/2 hr/mg protein±SEM.

Extracellular acidification and oxygen consumption rates were measured using a Seahorse XF24 Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA) according to manufacturer's instructions for the glycolysis stress test and mitochondrial stress test. Cells were seeded at equal densities and differentiated for 6 days at which point metabolic flux analysis was performed. For the glycolysis stress test, cells began in glucose-free stress test medium, to which glucose, oligomycin (an ATP coupler), and 2-deoxy-D-glucose (a glucose analog) were added sequentially to final concentrations of 10 mM, 1*μ*M, and 100 mM, respectively. For the mitochondrial stress test, cells began in stress test medium containing 10 mM glucose, to which oligomycin, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, an ATP uncoupler), and rotenone/Antimycin A (mitochondrial inhibitors) were added to final concentrations of 1*μ*M, 1*μ*M, and 0.5*μ*M/0.5*μ*M, respectively. In both tests, between the addition of each component, the oxygen consumption rate and extracellular acidification were measured as previouslydescribed \[[@r33]\].

Statistical analysis {#sec0060}
--------------------

The data are presented as mean±standard error of the mean with the exception of [Fig. 2 C](#jnd-2-4-jnd150119-g002){ref-type="fig"}, which presents data in box-and-whiskers format with the median, quartiles, and outliers depicted. For qRT-PCR analysis, statistical analysis was performed using qbase+. For all other experiments, statistical analysis was performed using SigmaPlot 11 (SyStat Software, Chicago, IL). When two groups were compared, differences were analyzed with a two-way Student's *t* test. For more than two groups, differences were compared using one-way analysis of variance (ANOVA) with Bonferroni *post hoc* comparisons. Probability *(p)* values less than 0.05 were considered statistically significant.

RESULTS {#sec0065}
=======

*Mss51* gene expression is modulated by TGF-β superfamily signaling {#sec0070}
-------------------------------------------------------------------

To examine modulation of *Mss51* expression, we first determined the time course of its expression *in vitro*. *Mss51* was expressed at low levels in proliferating C2C12 myoblasts, and significantly higher levels as cells differentiated into myotubes ([Fig. 1A](#jnd-2-4-jnd150119-g001){ref-type="fig"}). Myotubes were then differentiated for three days and treated with various TGF-β superfamily members as well as various inhibitors ([Fig. 1B](#jnd-2-4-jnd150119-g001){ref-type="fig"}). TGF-β superfamily members (myostatin, TGF-β1 and activin A) all increased *Mss51* expression in myotubes. The TGF-β1/2/3 neutralizing antibody 1D11 decreased *Mss51* expression and there was a trend toward decreased expression with ActRIIB-Fc treatment. IGF-1, which has several similar effects on skeletal muscle as myostatin inhibition including increasing proliferation and differentiation *in vitro* and muscle growth *in vivo* \[[@r34]\], also decreased *Mss51* expression. We examined other time points and saw the greatest effects on *Mss51* expression levels when the myotubes were differentiated for three days and no significant change seen when proliferating myoblasts were treated (data not shown). This may be because during differentiation, the cells are actively increasing *Mss51* expression and are therefore more responsive to exogenous signaling cues.

*Mss51* is predominantly expressed in glycolytic skeletal muscle {#sec0075}
----------------------------------------------------------------

To determine the tissue specificity of *Mss51*, we performed qRT-PCR using RNA isolated from the brain, heart, kidney, liver, small intestine, diaphragm, and quadriceps of 10-- 12 week-old female C57BL/6J mice. There were no significant differences between brain, heart, kidney, and liver, while expression was higher in the small intestine and diaphragm, approximately 20-fold above the expression level found in the brain. In the quadriceps, expression was approximately 150-fold higher compared to brain ([Fig. 2A](#jnd-2-4-jnd150119-g002){ref-type="fig"}).

We also examined the relative expression of *Mss51* in different skeletal muscle groups, selected based on their established fiber type distributions \[[@r35]\], listed from more oxidative to more glycolytic: soleus, diaphragm, long head of the triceps brachii, extensor digitorum longus (EDL), and white vastus lateralis (WVL) ([Fig. 2B](#jnd-2-4-jnd150119-g002){ref-type="fig"}). There were significant differences between muscle groups, with lower expression in the more oxidative soleus and diaphragm muscles, intermediate in the mixed-type long head of the triceps brachii, and higher expression in the glycolytic EDL and WVL. *Mss51* was highly expressed in muscles that are more glycolytic and dominated by type IIB fibers, while lowly expressed in predominantly oxidative muscles dominated by type I/IIA fibers.

To determine if the expression pattern was similar in humans, we examined the Genotype-Tissue Expression (GTEx) Portal database (<http://www.gtexportal.org>\[gtexportal.org\]). The GTEx Portal includes searchable RNA-seq data from over 40 tissue types of 175 humans \[[@r38]\]. Our search revealed *MSS51* to be expressed at much higher levels in skeletal muscle than any other tissue examined ([Fig. 2C](#jnd-2-4-jnd150119-g002){ref-type="fig"}).

*MSS51* is localized to the mitochondria {#sec0080}
----------------------------------------

To determine cellular localization of *MSS51*, human deltoid muscles from an open muscle biopsy of a living donor and from an autopsy were used to perform subcellular fractionation. Fractions of nuclear, cytoplasmic, and mitochondrial proteins were collected and used for SDS-PAGE and Western blotting. These data showed that *MSS51* protein co-fractionated with the mitochondrial fraction ([Fig. 3](#jnd-2-4-jnd150119-g003){ref-type="fig"}).

*Mss51* does not regulate proliferation and differentiation {#sec0085}
-----------------------------------------------------------

Using the CRISPR/Cas9 system for genome engineering, a double-strand break was introduced into the first exon of *Mss51* in C2C12 cells at the locus depicted in [Fig. 4A](#jnd-2-4-jnd150119-g004){ref-type="fig"}. Pooled populations of sorted cells, control (transfected with a plasmid encoding GFP) versus *Mss51*-disrupted (CRISPR/Cas9 dual expression plasmid co-transfected with a GFP reporter plasmid that only expressed GFP when CRISPR/Cas9 is expressed in the same cell), were collected and enriched as represented in [Fig. 4B](#jnd-2-4-jnd150119-g004){ref-type="fig"}. The *Mss51*-disrupted myotube population was a pool of many unique *Mss51* mutants including cells that have at least one wild-type allele. Relative *Mss51* expression in the pooled cells was determined using primers flanking the predicted double strand break, which demonstrated a significant decrease in total *Mss51* transcript in the differentiating *Mss51*-disrupted myotubes when compared to control cells ([Fig. 4C](#jnd-2-4-jnd150119-g004){ref-type="fig"}).

Myostatin, TGF-β, and IGF-1 all modulate myoblast proliferation and differentiation and, as shown in [Fig. 1B](#jnd-2-4-jnd150119-g001){ref-type="fig"}, also are associated with altered *Mss51* gene expression. For this reason, we examined cell proliferation and differentiation in *Mss51*-disrupted cells. Proliferation was unchanged compared to control cells, as measured by EdU incorporation ([Fig. 5A, B](#jnd-2-4-jnd150119-g005){ref-type="fig"}) and alamarBlue assay ([Supplementary Figure 1](#S1){ref-type="supplementary-material"}). Differentiation was also equivalent in *Mss51*-disrupted and control cell populations by myofusion index, the proportion of nuclei found in myosin heavy chain-positive fibers at day 5 post differentiation media ([Fig. 5C, D](#jnd-2-4-jnd150119-g005){ref-type="fig"}). Creatine kinase enzyme activity, a marker of differentiation, did not differ significantly between control and *Mss51*-disrupted myotubes after six days of differentiation ([Fig. 5E](#jnd-2-4-jnd150119-g005){ref-type="fig"}). Myotubes were differentiated for six days to ensure that stable levels of *Mss51* transcript and protein were present in control cells, corresponding to the greatest difference between control and disrupted populations. We also looked at expression of myogenic regulatory factors by qPCR and did not see meaningful differences between control and *Mss51*-disrupted cells (data not shown). Protein synthesis, as measured by puromycin incorporation using the SUnSET assay, was not altered in *Mss51*-disrupted myotubes after 6 days of differentiation ([Fig. 5F, G](#jnd-2-4-jnd150119-g005){ref-type="fig"}).

*Mss51*-disrupted myotubes are more metabolically active than wild-type myotubes {#sec0090}
--------------------------------------------------------------------------------

Myostatin knockout and *IGF-1* transgene expression lead to an alteration in fiber-type composition with a decrease in type 1 slow oxidative fibers and an increase in type IIB fast glycolytic fibers \[[@r9]\]. We therefore examined whether CRISPR/Cas9-mediated disruption of the *Mss51* locus altered expression of the various myosin heavy chain isoforms (MyHCs) expressed by C2C12 myotubes. In *Mss51*-disrupted C2C12 myotubes, embryonic MyHC *(Myh3)*, neonatal MyHC *(Myh8)*, and MyHC IIX *(Myh1)* were significantly decreased, MyHC IIB *(Myh4)* was significantly increased, and MyHC IIA *(Myh2)* and MyHC I *(Myh7)* were unchanged ([Fig. 6A](#jnd-2-4-jnd150119-g006){ref-type="fig"}). The changes exhibited in *Mss51*-disrupted myotubes indicated a shift towards more fast-twitch MyHC expression.

Since expression of MyHC isoforms typically coincide with metabolic properties of muscle, we evaluated whether *Mss51* modulates the mRNA expression of several key regulators of metabolism ([Fig. 6B](#jnd-2-4-jnd150119-g006){ref-type="fig"}). Consistent with a shift toward MyHC IIB expression, *Mss51*-disrupted myotubes displayed a downregulation of *PGC1α*, which among its many functions is the major factor in type I fiber type determination \[[@r43]\]. Cytochrome *c* oxidase subunit 2 *(Cox2)* gene expression was minimally increased but other genes involved with mitochondrial biogenesis (including *Nrf1, Nfe2l2,* citrate synthase, *ESRRα*) and genes of mitochondrial respiration (including *Atp5o, Alas1, Cox5b, Cycs*) were unchanged. *PGC1α* is a major player in mitochondrial biogenesis, and it is intriguing that we did not see greater alterations in other genes involved in mitochondrial biogenesis, indicating that the decreased *PGC1α* expression may be primarily linked to the shift in fiber type profile in cells deficient in *Mss51*. We evaluated *PGC1α* expression in proliferating and differentiating *Mss51*-disrupted myotubes and found similar levels in proliferating *Mss51*-disrupted myoblasts versus controls but lower levels in differentiated *Mss51*-disrupted myoblasts compared to controls ([Supplementary Figure 2](#S1){ref-type="supplementary-material"}).

Expression of the glycolytic gene hexokinase 2 *(Hk2)*, which has been shown to be more active in the glycolytic EDL muscle than the oxidative soleus muscle \[[@r44]\], was significantly increased in *Mss51*-disrupted myotubes ([Fig. 6B](#jnd-2-4-jnd150119-g006){ref-type="fig"}). Other genes that had significant changes in expression with decreased *Mss51* expression were *Cd36* (fatty acid translocase), *Fasn* (fatty acid synthase), and *Pdk4* (pyruvate dehydrogenase lipoamide kinase isozyme 4), which were all increased. The products of these genes are all critical in fatty acid utilization. Other genes involved in fatty acid oxidation (FAO) including *HSL* (hormone sensitive lipase) and *Acadl* (long chain specific acyl-coA dehydrogenase) were also increased to a lesser extent while other genes involved in FAO were unchanged.

Since yeast *Mss51* is a translational activator, we examined changes in protein expression via immunoblotting. We examined several mitochondrial markers, including cytochrome *c*, VDAC, CoxI, CoxIV, and pyruvate dehydrogenase, and did not detect any differences between *Mss51*-disrupted and control myotubes ([Supplementary Figure 3](#S1){ref-type="supplementary-material"}). We also examined markers of peroxisome proliferator-activated receptor gamma (PPAR*γ*)-regulated fatty acid metabolism, including AMP-activated protein kinase (AMPK*α*), SirT1, and GCN5L2 ([Fig. 6C](#jnd-2-4-jnd150119-g006){ref-type="fig"} and [Supplementary Figure 3](#S1){ref-type="supplementary-material"}). Of these, only AMPK*α* was increased in *Mss51*-disrupted myotubes. Activated, phosphorylated AMPK*α* (p-AMPK*α*) is a marker of cellular energy \[[@r45]\], and both total protein expression and p-AMPK*α* (relative to total AMPK*α*) were increased in myotubes with reduced *Mss51* expression ([Fig. 6C, D](#jnd-2-4-jnd150119-g006){ref-type="fig"}).

AMPK*α* activation switches off ATP consuming pathways and switches on ATP generating processes (glucose uptake and fatty acid oxidation) \[[@r46]\]. To determine if the increases in gene expression of fatty acid utilization and p-AMPK*α* described above resulted in increased ATP generation, we measured ATP content of populations of differentiated myotubes. Cellular ATP content was significantly increased in *Mss51*-disrupted myotubes ([Fig. 7A](#jnd-2-4-jnd150119-g007){ref-type="fig"}). To determine if fatty acid utilization was altered in *Mss51*-disrupted myotubes, we measured β-oxidation of radiolabeled palmitic acid in intact control and *Mss51*-disrupted myotubes ([Fig. 7B](#jnd-2-4-jnd150119-g007){ref-type="fig"}). *Mss51*-disrupted myotubes were shown to have a significantly higher β-oxidation activity.

To confirm the finding that reduced *Mss51* expression resulted in increased cellular metabolism as suggested by increased ATP production and increased β-oxidation of palmitic acid, glycolysis stress and mitochondrial stress tests were performed using the Seahorse XF24 Flux Analyzer. In the glycolysis stress test, the extracellular acidification rate was measured as an indicator of glycolysis when differentiated myotubes were perturbed. Baseline measurements were taken in glucose-free media before glucose, oligomycin, and 2-deoxy-D-glucose were injected to begin glycolysis, shut down the electron transport chain, and inhibit glycolysis, respectively. Between each treatment, the extracellular acidification rate was measured and plotted ([Fig. 7C](#jnd-2-4-jnd150119-g007){ref-type="fig"}), allowing for the calculation of several key parameters: glycolysis under normal conditions, maximal glycolytic capacity when the electron transport chain is disrupted, and glycolytic reserve. Comparing *Mss51*-disrupted and control myotubes, we found that *Mss51*-disrupted myotubes had significantly higher glycolysis, glycolytic capacity, and glycolytic reserve than wild-type myotubes ([Fig. 7D](#jnd-2-4-jnd150119-g007){ref-type="fig"}). We also performed a mitochondrial stress test, where cells were treated with oligomycin, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone, and Rotenone/Antimycin to inhibit Complex V, uncouple the proton gradient, and inhibit Complexes I and III, respectively. This allowed for the calculation of basal respiration, ATP production, maximal respiration, and spare respiratory capacity, all measured by changes in oxygen consumption rate ([Fig. 7E](#jnd-2-4-jnd150119-g007){ref-type="fig"}). We found that all metrics of mitochondrial respiration excluding proton leak were significantly increased in *Mss51*-disrupted cells ([Fig. 7F](#jnd-2-4-jnd150119-g007){ref-type="fig"}), indicating that cells that expressed less *Mss51* had higher metabolic activity, resulting in higher levels of respiration, glycolysis, and ATP production.

DISCUSSION {#sec0095}
==========

In this report, we introduce mammalian *Mss51* as a muscle-specific gene regulated by members of the TGF-β superfamily. Mammalian *Mss51* initially came to attention as one of the most consistently downregulated genes in gene profiling studies of myostatin inhibition \[[@r19]\]. Given myostatin's role in skeletal muscle development, postnatal growth and regeneration, we originally postulated that *Mss51* might have a role in myoblast proliferation or differentiation but this was not supported by assays on C2C12 myoblasts in which *Mss51* was genetically disrupted ([Fig. 5](#jnd-2-4-jnd150119-g005){ref-type="fig"}). Rather, *Mss51* appears to modulate other aspects of TGF-β signaling in skeletal muscle including fiber type determination and metabolism. The observation that myostatin, TGF-β1, activin A and IGF-1 all modulate expression of *Mss51* suggest that it may be a common effector of these growth factors which converge to regulate metabolic adaptations ([Fig. 1](#jnd-2-4-jnd150119-g001){ref-type="fig"}).

*Mss51* is expressed almost exclusively in skeletal muscle in mice and humans. In mice, it is expressed most abundantly in muscles rich in glycolytic type II fibers and 20- to 25-fold less in those rich in oxidative type I fibers ([Fig. 2](#jnd-2-4-jnd150119-g002){ref-type="fig"}). Genetic disruption of *Mss51* shifts the myosin heavy chain expression profile toward a more glycolytic phenotype dominated by Type IIB myosin heavy chain ([Fig. 6](#jnd-2-4-jnd150119-g006){ref-type="fig"}). This is consistent with the effects of myostatin gene deletion and *IGF-1* transgene overexpression on fiber type composition which cause a similar shift toward a more glycolytic phenotype *in vivo* \[[@r9]\]. PGC1*α*, which is a major determinant of type 1 fiber formation, has been shown to be decreased in myostatin-null mice and muscle-specific *IGF-1* transgenic mice \[[@r11]\]. Further, in a transgenic model of overexpression of activated Akt1, a shift toward increased type IIB fibers was shown to accompany an increase in *Hk2* expression and a decrease in *PGC1α* expression alongside increased metabolic parameters \[[@r48]\]. Consistent with these findings, *PGC1α* is downregulated and *Hk2* is upregulated in *Mss51*-disrupted myotubes which have increased MyHC IIB expression compared to control myotubes ([Fig. 6](#jnd-2-4-jnd150119-g006){ref-type="fig"}).

Although mammalian *Mss51* has a limited similarity to its yeast ortholog *Mss51* (19% amino acid identity shared only across the zf-MYND domain), both proteins co-localize with mitochondria ([Fig. 3](#jnd-2-4-jnd150119-g003){ref-type="fig"}, \[[@r24]\]). Yeast Mss51 is a translational activator of Cox1 but *Mss51*-disrupted myotubes did not show a reduction in CoxI or CoxIV protein, suggesting its function is not conserved across species ([Supplementary Figure 3](#S1){ref-type="supplementary-material"}). Conversely, myotubes deficient in Mss51 displayed increased ATP production, β-oxidation and activation of AMPK*α*, a marker of cellular metabolic state ([Figs. 6](#jnd-2-4-jnd150119-g006){ref-type="fig"} and [7](#jnd-2-4-jnd150119-g007){ref-type="fig"}). Glycolysis and mitochondrial respiration are both increased after *Mss51* disruption ([Fig. 7](#jnd-2-4-jnd150119-g007){ref-type="fig"}). While the specific actions of Mss51 on cellular metabolism remain to be determined, it appears that there is a shift from glucose to fatty acid utilization occurring when there is less Mss51 present. β-oxidation is increased in *Mss51*-disrupted cells ([Fig. 7B](#jnd-2-4-jnd150119-g007){ref-type="fig"}) and several genes involved in fatty acid metabolism *(HSL, Acadl, Cd36, Fasn)* are upregulated. Further, increased expression of *Pdk4* and activation of AMPK*α* would predict a shift toward fatty acid utilization. Although the relationship between lipid balance and muscle insulin sensitivity continues to be explored, one model of obesity-associated insulin resistance posits intramyocellular lipid content as a principal contributor \[[@r49]\]. Myostatin inhibitors have been shown to prevent diet-induced obesity and insulin resistance in a number of models \[[@r17]\]. The possibility that these effects are in part mediated by Mss51 is consistent with the downregulation of *Mss51* by myostatin inhibitors and corresponding upregulation of genes involved in fatty acid metabolism.

Multiple myostatin inhibitors are currently in clinical trials for the treatment of neuromuscular disease (ClinicalTrials.gov Identifiers: NCT012310763, NCT02515669, NCT01519349 and NCT01423110). While these trials hope to increase muscle function by stimulating muscle growth and regeneration, inhibition of myostatin is also likely to have metabolic effects on skeletal muscle. Preclinical work by our group and others, suggest that *Mss51* will be downregulated by myostatin inhibition \[[@r19]\]. The current study suggests that this will have positive effects on bioenergetics, increasing cellular ATP. However, there are limitations to the current *in vitro* study in which, necessarily, only basal states are assayed and glucose and glutamine are the primary fuels of cellular metabolism. Additionally, the cell population characterized in this present study expresses a low level of *Mss51*, albeit significantly less than control populations, which may obscure changes that would occur in its complete absence. *In vivo* studies of *Mss51* knockout animals using stimuli that modulate fatty acid oxidation and mitochondrial biogenesis will be necessary to further elucidate *Mss51* function.
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![*Mss51* expression *in vitro*. (A) *Mss51* mRNA expression measured by qRT-PCR in proliferating and differentiating C2C12 cells. Expression level is normalized to proliferating (Day 0) cells using the reference gene *TBP*. (B) *Mss51* expression in differentiated C2C12 myotubes treated with various growth factors and inhibitors: 300 ng/mL myostatin, 5*μ*g/mL ActRIIB-Fc, 50 ng/mL TGF-β1, 10*μ*g/mL TGF-β neutralizing antibody 1D11, 20 ng/mL Activin A, and 100 ng/mL IGF-1. Expression level is normalized to control (untreated) cells using reference genes β2 *m* and *TBP*. For (A) and (B), significant differences between groups were determined by a one-way ANOVA (*n* = 3, *p* \<  0.01) with Bonferroni *post hoc* comparisons. The annotation above each bar indicates statistically significant differences between the means in each group at *p* \<  0.05: Groups sharing a letter designation were not significantly different from each other, while groups not sharing a letter were significantly different.](jnd-2-4-jnd150119-g001){#jnd-2-4-jnd150119-g001}

![*Mss51* tissue expression. (A) *Mss51* mRNA expression measured by qRT-PCR in brain, heart, kidney, liver, small intestine, diaphragm, and quadriceps of 10-- 12 week-old female C57BL/6J mice, normalized to the quantity found in the brain using the reference gene *Pgk1* (*n* = 3). (B) *Mss51* mRNA expression in soleus, diaphragm, long head of triceps brachii, extensor digitorum longus, and white vastus lateralis of the quadriceps of 10-- 12 week-old female C57BL/6J mice, normalized to the expression levels found in the soleus using reference genes *Pgk1* and *TBP* (*n* = 3). (C) *MSS51* expression across human tissue types determined by RNA-seq from the Genotype-Tissue Expression (GTEx) Portal showing *MSS51* reads per kilobase per million reads mapped (RPKM). Data were downloaded from GTEx Portal on June 17, 2015. For qRT-PCR experiments, groups were significantly different from each other as determined by a one-way ANOVA (*n* = 3, *p* \<  0.01) and Bonferroni *post hoc* comparisons. Different letters above each bar signify statistically significant differences between the means in each group at *p* \<  0.05.](jnd-2-4-jnd150119-g002){#jnd-2-4-jnd150119-g002}

![Subcellular localization of *MSS51*. Subcellular fractionation was performed on human deltoid samples from a biopsy and an autopsy and resulting fractions were subjected to SDS-PAGE. Immunoblotting was performed with the only current antibody specific to *MSS51* (anti-human *MSS51*, Acris Antibodies, San Diego, CA, USA) showing a band in the mitochondrial fraction of the predicted protein product size, 51 kDa. Loading controls were VDAC (mitochondrial), GAPDH (cytoplasmic), and Histone H3 (nuclear).](jnd-2-4-jnd150119-g003){#jnd-2-4-jnd150119-g003}

![CRISPR/Cas9-disruption of *Mss51* locus in C2C12 myoblasts. (A) Schematic of the*Mss51* genomic locus with the CRISPR guide RNA (gRNA) target sequence enlarged, predicted cut site marked in red, exons marked in black, UTRs in white. At the cut site, a double-strand break occurred and was re-sealed by non-homologous end joining. (B) Production of *Mss51*-disrupted cells was achieved by co-transfection of a dual-expression plasmid encoding the CRISPR gRNA (red) and the Cas9 endonuclease (blue), and a reporter plasmid encoding a disrupted GFP with two homology arms (dark green) flanking the CRISPR target site (red), which was cleaved by Cas9, re-sealed by homology-directed repair, and expressed functional GFP. Two populations of GFP-positive cells were collected by FACS sorting and expanded for further analysis -- *Mss51*-disrupted cells were collected as shown and in parallel, control cells were transfected with a GFP expression plasmid and subjected to the same FACS process. (C) *Mss51* expression measured by qRT-PCR in control and *Mss51*-disrupted populations over 6 days of differentiation, normalized to expression in proliferating control cells (Day 0) using reference genes *Tfam* and *TBP* (*n* = 3). ^\*\*^*p* \<  0.01,^\*\*\*^*p* \<  0.001.](jnd-2-4-jnd150119-g004){#jnd-2-4-jnd150119-g004}

![*Mss51*-disrupted myoblasts proliferate and differentiate normally. (A) Proliferating control and *Mss51*-disrupted myoblasts labeled with EdU (red) and Hoeschst 33342 (blue). (B) Quantification of EdU staining (*n* = 6 wells imaged per sample). (C) Representative myosin heavy chain (MF20, green) staining of control and *Mss51*-disrupted myotubes 2 days after induction of differentiation with nuclei stained by DAPI (blue). (D) Quantification of fusion index (percentage of nuclei found in MF20+ myotubes, *n* = 6). (E) Creatine kinase (CK) activity in myotubes after 6 days of differentiation. (F) Protein synthesis rates as measured by puromycin incorporation on the left and total protein stained by SYPRO Ruby on the right after 6 days of differentiation. (G) Densitometric analysis of SUnSET assay as shown in F, normalized to SYPRO Ruby-stained total protein (*n* = 3). Differences between groups were not statistically significant.](jnd-2-4-jnd150119-g005){#jnd-2-4-jnd150119-g005}

![Gene and protein expression in *Mss51*-disrupted differentiated myotubes (A) Myosin heavy chain expression measured by qRT-PCR in control and *Mss51*-disrupted C2C12 myotubes, normalized to expression levels in control myotubes using reference genes *Tfam* and *TBP* (*n* = 3). (B) Expression of metabolic genes in control and *Mss51*-disrupted C2C12 myotubes, normalized to expression levels in control myotubes using reference genes *Tfam* and *TBP* (*n* = 3). (C) Western blots of control and*Mss51*-disrupted C2C12 myotubes examining expression and phosphorylation of AMPK*α*. (D) Densitometric analysis of AMPK*α* expression normalized to GAPDH and of AMPK*α* phosphorylation normalized to both GAPDH and total AMPK*α* (*n* = 3). ^\*^*p* \<  0.05, ^\*\*^*p* \<  0.01.](jnd-2-4-jnd150119-g006){#jnd-2-4-jnd150119-g006}

![Glycolysis and Oxidative Phosphorylation in *Mss51*-disrupted cells. (A) ATP production in control and *Mss51*-disrupted myotubes (*n* = 6). (B) Activity of C~16 :0~ fatty acid β-oxidation in control and *Mss51*-disrupted myotubes (*n* = 6). (C) Glycolysis stress test measuring the extracellular acidification rate (ECAR) in control and *Mss51*-disrupted myotubes treated with glucose, oligomycin, and 2-deoxy-D-glucose. (D) Glycolysis, glycolytic capacity, and glycolytic reserve calculated from the glycolysis stress test (*n* = 10). (E) Mitochondrial stress test results comparing oxygen consumption rates (OCR) between control and *Mss51*-disrupted myotubes treated with oligomycin, carbonyl cyanide-p-trifluoromethoxyphen (FCCP), and Antimycin A/Rotenone. (F) Basal respiration, ATP production, proton leak, maximum respiration, and spare respiratory capacity as calculated from the mitochondrial stress test (*n* = 10). ^\*^*p* \<  0.05, ^\*\*\*^*p* \<  0.001.](jnd-2-4-jnd150119-g007){#jnd-2-4-jnd150119-g007}
